GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Medicine Co 600216.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

10.98

-1.44%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zhejiang Medicine Co

Its shares trade on Shanghai under the ticker 600216.SS. It has been listed since 21 October 1999. In the fiscal year to 31 December 2025, it reported revenue of CN¥8.88bn and net income of CN¥873.4m. At that date it held total assets of CN¥14.09bn and shareholders' equity of CN¥10.94bn.

Zhejiang Medicine Co., Ltd. engages in the production and sale of pharmaceutical products. The company is headquartered in Shaoxing, Zhejiang. The firm mainly provides nourishments for animals and human, health care products, and chemicals and chemical raw materials, among others. The firm's products include synthetic vitamin E, natural vitamin E soft capsules, Beta carotene, vancomycin hydrochloride for injection and teicoplanin for injection, among others. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Oct 1999
Employees
6,208
Website
zmc.top ↗

Leadership

Pay as last reported

  • Mr. Nanxing LiChairman of the Board, since 2018CN¥2.5m
  • Mr. Hongwei WangPresident, Director, since 2018CN¥2.6m
  • Mr. Zhong LiuVice Chairman of the Board, since 2023
  • Mr. Qirong LiChief Financial OfficerCN¥1.8m
  • Ms. Liping LiangVice PresidentCN¥2.0m
  • Mr. Jianhong PingVice PresidentCN¥1.9m
  • Mr. Xiaoping WangVice PresidentCN¥2.1m
  • Mr. Yongbin AnSenior Executive OfficerCN¥2.2m
  • Mr. Minzhi ShaoSecretary of the BoardCN¥181,500
  • Mr. Hongyu CangDirector
  • Mr. Zhenhua ChuDirectorCN¥1.9m
  • Ms. Birong LiangDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
77
Environment
91
Social
99
Governance
40
Direct emissions (scope 1)
122,299.79 t
Energy emissions (scope 2)
521,257.04 t
Women in the workforce
38.55546%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Shaoxing, Zhejiang with 6,208 employees
  • Produces and sells pharmaceutical products including synthetic vitamin E and natural vitamin E soft capsules
  • Operates in both domestic and overseas markets

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on product quality or market share provided
  • No information on financial performance or competitive advantages

Opportunities

  • Expanding into animal and human nourishment markets
  • Growing demand for health care products and chemicals
  • Potential for increased overseas market distribution

Threats

  • No specific threats mentioned in the provided information
  • No details on regulatory challenges or market competition
  • No information on economic or industry risks

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.